TrialLeukemia2017

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).

G Bug et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.